Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions. The green light ...

An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...

A pharmacist has issued a warning over using nasal spray products when you've got a blocked or stuffy nose. Decongestant nasal sprays are medications designed to provide temporary relief from ...

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal ...

Compared to liquid-based DHE nasal products – which include Impel Pharma's Trudhesa and Bausch Health's Migranal – Satsuma's product offers greater stability, less variable dosing, and a ...

The Joico Humidity Blocker+ Protective Finishing Spray is a smoothing, shine-inducing styling mist designed for all hair types. Similar to hairspray in consistency and application method ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...